Adherence, persistence, and real-life effectiveness of alirocumab 300 mg for people with high cholesterol in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, real-world study of patients in Italy who are being treated with alirocumab 300 mg, tracking how well they adhere to and persist with therapy and how their cholesterol levels respond. Investigators will collect clinical data and prescription/visit records from participating patients treated at the enrolling center. Eligible participants are adults aged 18–80 who are already receiving alirocumab 300 mg and provide informed consent. The design is non-randomized and reflects routine clinical practice rather than a controlled interventional protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Patients under alirocumab 300mg treatment.

Exclusion Criteria:

* Age \< 18 years o \> 80 years;
* Patients who refuse to participate and to sign informed consent.

Where it's running

• Federico II University of Naples, Department of Advanced Biomedical Sciences
  Naples, Napoli, Italy Recruiting

Study contacts

• Study coordinator: Pasquale Perrone Filardi
• Email: fpperron@unina.it
• Phone: +390817462224

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Linking social care with healthcare to help manage chronic diseases

  This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.

  Recruiting at 2 sites University of Arizona · Tucson, Arizona and 1 other locations · NCT07799961

• A new combination pill to lower LDL cholesterol in adults who haven’t taken cholesterol medicine before

  This study tests whether a fixed-dose combo pill of laroprovstat and rosuvastatin can lower LDL-C better than laroprovstat alone, rosuvastatin alone, or placebo in adults without prior lipid therapy.

  Recruiting at 12 sites Phase 3 AstraZeneca · Dothan, Alabama and 151 other locations · NCT07619131

• Fixed-dose combination of laroprovstat/rosuvastatin vs rosuvastatin alone for high cholesterol

  This study tests whether a fixed-dose combo pill of laroprovstat and rosuvastatin lowers LDL cholesterol better than rosuvastatin alone in adults with high cholesterol who have or are at risk for cardiovascular disease.

  Recruiting at 16 sites Phase 3 AstraZeneca · Sun City West, Arizona and 44 other locations · NCT07619118

• Obicetrapib vs. bempedoic acid for high-risk high cholesterol patients

  This phase 3 study tests whether obicetrapib can lower LDL-C more than bempedoic acid in adults with primary non-familial hypercholesterolemia or mixed dyslipidemia who still have high LDL-C despite maximum tolerated therapy.

  Recruiting Phase 3 A. Menarini International Licensing S.A. · Stockton-on-Tees · NCT07614958

• Combination therapy with QCZ484 and Inclisiran for hypertension with high cholesterol

  This study tests whether the drug QCZ484, alone or with Inclisiran, lowers cholesterol and helps blood pressure in adults with hypertension and high cholesterol.

  Recruiting at 29 sites Phase 2 Novartis · Foley, Alabama and 28 other locations · NCT07610278

• Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance

  This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.

  Recruiting Phase 4 University Medical Centre Ljubljana · Ljubljana · NCT07581808

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.